Research Fellowship

Lewis教授是一名分子药理学家，他对发现新的毒液肽和雪卡毒素感兴趣，并利用先进的生化和光谱方法确定它们如何与靶膜蛋白相互作用。然后对感兴趣的肽进行修饰以提高效力和选择性。那些具有适当特性的药物获得了专利，并开发用于临床应用，使用的方法成功应用于Xen2174， Xen2174是我共同发现的一种康多肽类似物，目前正在进行II期临床试验，用于治疗严重疼痛。

Professor Lewis is a molecular pharmacologist interested in discovering new venom peptides and ciguatoxins and determining how they interact with the membrane proteins they target using advanced biochemical and spectroscopic methods. Peptides of interest are then modified to improve potency and selectivity. Those with appropriate properties are patented and developed for clinical applications using approaches successfully applied to Xen2174, a conopeptide analogue I co-discovered that is now in Phase II clinical trials for severe pain.